| 汪笑秋,江锦红,曲志刚,马光丽,刘永华,章俏雷,王晓丽,方炳木.ESHAP方案及GDP方案治疗复发性及难治性非霍奇金淋巴瘤的疗效对比研究[J].浙江中西医结合杂志,2016,26(5): |
| ESHAP方案及GDP方案治疗复发性及难治性非霍奇金淋巴瘤的疗效对比研究 |
| Compared the efficacy of ESHAP regimen and GDP regimen on relapsed and refractory non-Hodgkin lymphoma |
| 投稿时间：2015-07-21 修订日期：2015-10-18 |
| DOI： |
| 中文关键词: ESHAP方案 GDP方案 复发性及难治性非霍奇金淋巴瘤 |
| 英文关键词:ESHAP regimen,GDP regimen,relapsed and refractory non-Hodgkin lymphoma |
| 基金项目: |
|
| 摘要点击次数: 876 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的 对比ESHAP方案及GDP方案治疗复发及难治性非霍奇金淋巴瘤的临床疗效。方法 选择2012年1月-2014年12月于我院接受ESHAP方案或GDP方案的复发性及难治性NHL患者51例,其中ESHAP方案组27例,GDP方案组24例,均接受2周期以上化疗,对比两种方案的总有效率及不良反应的发生率。结果 (1)ESHAP方案组CR 8例,PR 10例,SD 5例,PD 4例,总有效率为66.67%,GDP方案组CR 6例,PR 9例,SD 6例,PD 3例,总有效率为62.5%,二者之间无明显差异,P＞0.05。(2)ESHAP方案组白细胞减少24例,血小板减少20例,胃肠道反应15例,肝功能异常10例；GDP方案组白细胞减少15例,血小板减少11例,胃肠道反应14例,肝功能异常15例；GDP方案组白细胞减少、血小板减少的发生率明显低于ESHAP方案组,差异有统计学意义,P＜0.05；胃肠道反应、肝功能异常的发生率无明显差异,P＞0.05。结论 ESHAP方案及GDP方案治疗复发及难治性非霍奇金淋巴瘤的疗效无明显差别,GDP方案的骨髓抑制不良反应的发生率较ESHAP方案低,更易被患者所接受。 |
| 英文摘要: |
| Objective TO compared the efficacy of ESHAP regimen and GDP regimen on relapsed and refractory non-Hodgkin lymphoma. Metheds We select 51 cases of relapsed and refractory non-Hodgkin lymphoma patients who received ESHAP regimen and GDP regimen treatment.27 cases received ESHAP regimen and 24 case received GDP regimen more than 2 cycles of chemotherapy.Compared the two regimens’total efficiency and the incidence of adverse reactions.Results (1)In ESHAP regimen,8 cases were complete remission,10 cases were partial remission,5 cases were stable disease and 4 cases were progression disease,the total efficiency was 66.67%.In GDP regimen,6 cases were complete remission,9 cases were partial remission,6 cases were stable disease and 3 cases were progression disease,the total efficiency was 62.5%.The total efficiency of ESHAP regimen and GDP regimen were not significant difference,P＞0.05.(2)In ESHAP regimen, 24 cases got leukocytopenia,11 cases got thrombocytopenia,15 cases got gastrointestinal reactions and 15 cases got hepatic dysfunction.In GDP regimen,15 cases got leukocytopenia,11cases got thrombocytopenia,14cases got gastrointestinal reactions and 15 cases got hepatic dysfunction.The incidence of leukocytopenia and hrombocytopenia in GDP regimen were lower than ESHAP regimen,P＜0.05.The incidence of gastrointestinal reactions and hrombocytopenia of the two regimen were not significant difference,P＞0.05.Conclusion The efficacy of ESHAP regimen and GDP regimen on relapsed and refractory non-Hodgkin lymphoma had no significant difference.The incidence of myelosuppression of GDP regimen was lower than ESHAP regimen.And it was more easily accepted by patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
